Michael Quigley

TL;DR: Data suggest that anti-CTLA-4 promotes antitumor activity by a selective reduction of intratumoral Tregs along with concomitant activation of Teffs.

TL;DR: This work reports that V-domain immunoglobulin suppressor of T cell activation (VISTA) engages and suppresses T cells selectively at acidic pH such as that found in tumour microenvironments, thereby mediating resistance to anti-tumour immune responses.

TL;DR: In vitro studies with combined ipilimumab and nivolumab showed enhanced cytokine secretion in superantigen stimulation of human peripheral blood lymphocytes and in mixed lymphocyte response assays, and dose-dependent immune-related gastrointestinal inflammation was observed with the combination therapy; this response had not been observed in previous single agent cynomolgus studies.

TL;DR: The findings indicate that the PD-1/PD-L pathway can be hijacked as an immune escape mechanism in hematological malignancies and suggest that blocking thePD-1 immune checkpoint offers an appealing immunotherapeutic strategy following alloSCT in patients with recurrent or relapsed disease.

TL;DR: It is demonstrated that combining therapeutic approaches may simultaneously remove inhibitory immune populations and sustain endogenous antitumor immune responses to successfully impair cancer progression and provide rationale for the combination of two distinct immunotherapies to improve clinical outcome.